RESUMEN
BACKGROUND: Low-titer group O whole blood (LTO-WB) has recently gained popularity in trauma centers for the acute resuscitation of hemorrhagic shock. However, limited supplies of Rh- product prevent implementation and strain sustainability at many trauma centers. We set out to identify whether Rh+ LTO-WB could be safely substituted for RH- product, regardless of patient's Rh status. METHODS: Following Institutional Review Board approval, information on all trauma patients receiving prehospital or emergency department transfusion of uncrossed, emergency release LTO-WB (11/17-10/19) were evaluated. Patients were first divided into those who received Rh- versus Rh+ product, the assessed by Rh of the recipient. Serial hemolysis panels, transfusion reactions, and outcomes were compared. RESULTS: Six hundred thirty-seven consecutive trauma patients received emergency release LTO-WB. Of these, 448 received Rh+ product, while 189 received Rh- LTO-WB. Patients receiving Rh+ product were more likely to be men (81 vs. 70%) and have lower field blood pressure (median 99 vs. 109) and GCS (median 7 vs. 12); all p < 0.05. There were no differences in blood product volume, hemolysis laboratories, transfusion reactions, complications, or survival. We then separated patients by Rh status (577 were Rh+, 70 were Rh-). Rh- patients were older (median age 54 vs. 39), more likely to be women (57 vs. 26%), and more likely to have sustained blunt trauma than their Rh+ counterparts (92 vs. 70%); all p < 0.05. There were no differences in hemolysis laboratories, transfusion reactions, complications, or survival between Rh+ and Rh- patients, regardless of Rh product received. CONCLUSION: When Rh- whole blood is unavailable or in short supply, Rh+ LTO-WB appears to be a safe alternative for the resuscitation of hemorrhagic shock in both Rh+ and Rh- patients. Use of Rh+ product may help trauma centers incorporate LTO-WB into their hospital and improve sustainability of such programs. LEVEL OF EVIDENCE: Therapeutic, Level III.
Asunto(s)
Transfusión Sanguínea/métodos , Choque Hemorrágico/terapia , Reacción a la Transfusión/prevención & control , Centros Traumatológicos/organización & administración , Heridas y Lesiones/terapia , Sistema del Grupo Sanguíneo ABO/inmunología , Adulto , Femenino , Humanos , Puntaje de Gravedad del Traumatismo , Masculino , Persona de Mediana Edad , Evaluación de Programas y Proyectos de Salud , Resucitación/métodos , Isoinmunización Rh/sangre , Isoinmunización Rh/prevención & control , Reacción a la Transfusión/sangre , Centros Traumatológicos/estadística & datos numéricos , Resultado del Tratamiento , Heridas y Lesiones/sangre , Heridas y Lesiones/complicaciones , Heridas y Lesiones/diagnósticoAsunto(s)
Anemia/terapia , Transfusión de Sangre Intrauterina/métodos , Complicaciones Hematológicas del Embarazo/terapia , Isoinmunización Rh/terapia , Sistema del Grupo Sanguíneo Rh-Hr/sangre , Adulto , Anemia/sangre , Transfusión Sanguínea/métodos , Transfusión Sanguínea/estadística & datos numéricos , Transfusión de Sangre Intrauterina/estadística & datos numéricos , Femenino , Humanos , Recién Nacido , Embarazo , Complicaciones Hematológicas del Embarazo/sangre , Isoinmunización Rh/sangre , Resultado del TratamientoRESUMEN
Red blood cell alloimmunisation after transfusion of red blood cell concentrates carries a risk for every recipient. This risk is particularly high for patients with conditions such as sickle cell disease. However, red blood cell alloimmunisation can also occur after platelet concentrate transfusion. All blood group systems other than ABO are affected, and there are several mechanisms responsible for this alloimmunisation. The practical implications of this are a need to match red blood cell concentrates in all alloimmunised patients and, in pregnant women, recongnition of the risk of developing haemolytic disease of the foetus and newborn. Several measures can be taken to prevent alloimmunisation: in the case of the D antigen, for example, anti-RhD immunoglobulins can be infused before transfusing platelet concentrates from an RhD-positive donor in a RhD-negative recipient.
Asunto(s)
Antígenos de Grupos Sanguíneos/inmunología , Incompatibilidad de Grupos Sanguíneos/etiología , Plaquetas/inmunología , Eritrocitos/inmunología , Isoanticuerpos/sangre , Transfusión de Plaquetas/efectos adversos , Antígenos de Superficie/inmunología , Incompatibilidad de Grupos Sanguíneos/sangre , Incompatibilidad de Grupos Sanguíneos/inmunología , Tipificación y Pruebas Cruzadas Sanguíneas , Micropartículas Derivadas de Células/inmunología , Femenino , Humanos , Inflamación , Isoanticuerpos/biosíntesis , Isoanticuerpos/inmunología , Masculino , Embarazo , Complicaciones del Embarazo/sangre , Complicaciones del Embarazo/inmunología , Isoinmunización Rh/sangre , Isoinmunización Rh/etiología , Isoinmunización Rh/inmunología , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Globulina Inmune rho(D)/biosíntesis , Globulina Inmune rho(D)/sangre , Globulina Inmune rho(D)/inmunologíaRESUMEN
BACKGROUND: All non-sensitized Rhesus D (RhD)-negative pregnant women in Germany receive antenatal anti-D prophylaxis without knowledge of fetal RhD status. Non-invasive prenatal testing (NIPT) of cell-free fetal DNA in maternal plasma could avoid unnecessary anti-D administration. In this paper, we systematically reviewed the evidence on the benefit of NIPT for fetal RhD status in RhD-negative pregnant women. METHODS: We systematically searched several bibliographic databases, trial registries, and other sources (up to October 2019) for controlled intervention studies investigating NIPT for fetal RhD versus conventional anti-D prophylaxis. The focus was on the impact on fetal and maternal morbidity. We primarily considered direct evidence (from randomized controlled trials) or if unavailable, linked evidence (from diagnostic accuracy studies and from controlled intervention studies investigating the administration or withholding of anti-D prophylaxis). The results of diagnostic accuracy studies were pooled in bivariate meta-analyses. RESULTS: Neither direct evidence nor sufficient data for linked evidence were identified. Meta-analysis of data from about 60,000 participants showed high sensitivity (99.9%; 95% CI [99.5%; 100%] and specificity (99.2%; 95% CI [98.5%; 99.5%]). CONCLUSIONS: NIPT for fetal RhD status is equivalent to conventional serologic testing using the newborn's blood. Studies investigating patient-relevant outcomes are still lacking.
Asunto(s)
Pruebas Prenatales no Invasivas/estadística & datos numéricos , Complicaciones Hematológicas del Embarazo/diagnóstico , Isoinmunización Rh/diagnóstico , Sistema del Grupo Sanguíneo Rh-Hr/sangre , Globulina Inmune rho(D)/uso terapéutico , Quimioprevención/métodos , Femenino , Sangre Fetal/inmunología , Humanos , Recién Nacido , Uso Excesivo de los Servicios de Salud/prevención & control , Pruebas Prenatales no Invasivas/métodos , Embarazo , Complicaciones Hematológicas del Embarazo/sangre , Complicaciones Hematológicas del Embarazo/prevención & control , Atención Prenatal/métodos , Isoinmunización Rh/sangre , Isoinmunización Rh/prevención & controlRESUMEN
BACKGROUND: Rhesus D (RhD) incompatibility is still the most important cause of hemolytic disease of the fetus and newborn (HDFN) worldwide. The aim of this study was to investigate the incidence, causes, and consequences of anti-D alloimmunizations in pregnancy in Iceland, prior to implementation of targeted routine antenatal anti-D prophylaxis (RAADP) in 2018. STUDY DESIGN AND METHODS: This was a nation-wide cohort study of 130 pregnancies affected by RhD alloimmunization in Iceland in the period from 1996 through 2015. Data were collected from transfusion medicine databases, medical records, and the Icelandic Medical Birth Register. RESULTS: Of 130 RhD alloimmunizations, 80 cases (61.5%) represented new RhD immunization in the current pregnancy. Sensitization was discovered in the third trimester in 41 (51.3%) and occurred in the first pregnancy in 14 cases (17.5%). The most likely causative immunization event was the index pregnancy for 45 (56.25%), a previous pregnancy/birth for 26 (32.5%), abortion for 3 (3.75%), and unknown for 6 women (7.5%). Higher anti-D titers were associated with shorter gestational length, cesarean sections, positive direct antiglobulin test (DAT), and severe HDFN. Intrauterine transfusion (IUT) was performed in five pregnancies (3.8%), and 35 of 132 (26.5%) live-born neonates received treatment for HDFN; 32 received phototherapy (24.2%), 13 exchange transfusion (9.8%), and seven simple blood transfusion (5.3%). CONCLUSION: In about half of cases, RhD alloimmunization was caused by the index pregnancy and discovered in the third trimester. Thus, the newly implemented RAADP protocol should be effective in reducing the incidence of RhD immunization in Iceland in the future.
Asunto(s)
Transfusión de Sangre Intrauterina , Nacimiento Vivo , Diagnóstico Prenatal , Isoinmunización Rh , Globulina Inmune rho(D)/sangre , Adulto , Anemia Hemolítica Autoinmune/sangre , Anemia Hemolítica Autoinmune/diagnóstico , Anemia Hemolítica Autoinmune/epidemiología , Anemia Hemolítica Autoinmune/prevención & control , Femenino , Humanos , Islandia , Recién Nacido , Embarazo , Estudios Retrospectivos , Isoinmunización Rh/sangre , Isoinmunización Rh/diagnóstico , Isoinmunización Rh/epidemiología , Isoinmunización Rh/prevención & controlRESUMEN
The authors report a term male neonate who was born in unexpectedly poor condition with low Apgar scores and low venous cord gas pH. He required admission to the neonatal unit and was found to have developed haemolytic anaemia with associated hydrops, following a presumed severe antenatal insult. Antenatally, low levels of anti-E antibodies (titre 8) had been detected at 28 weeks' gestation. Following the British Society for Haematology and local neonatal team guidance, advice was given for cord direct antiglobulin test, full blood count and bilirubin at delivery. This case highlights the rare case of haemolytic disease of the fetus and newborn on a background of maternal low titre anti-E antibodies.
Asunto(s)
Eritroblastosis Fetal/sangre , Isoinmunización Rh/sangre , Sistema del Grupo Sanguíneo Rh-Hr/sangre , Adulto , Femenino , Humanos , Recién Nacido , Masculino , EmbarazoRESUMEN
Here in this report a 31 year old pregnant woman with positive serum antiglobulin test against anti-D antierythrocyte antibodies who was treated succesfully with double filtration plasmapheresis (DFPP) is presented. The DFPP was started in the early stage of pregnancy together with intravenous immunoglobulin therapy and the antierythrocyte antibody titer of the patient was successfully maintained in a stable level below 1:64 dilution. She delivered successfully on the 30th week of gestation. The favorable outcome of this patient implies that DFPP is an effective and safe treatment modality in pregnant women with red cell alloimmunization.
Asunto(s)
Plasmaféresis/métodos , Isoinmunización Rh/sangre , Globulina Inmune rho(D)/sangre , Adulto , Femenino , Humanos , EmbarazoRESUMEN
BACKGROUND: The determination of foetal Rhesus D (RHD) status allows appropriate use of IgRh prophylaxis by restricting its use to cases of RHD feto-maternal incompatibilities. There is a degree of uncertainty about the cost-effectiveness of foetal RHD determination, yet screening programs are being introduced into clinical practice in many countries. This paper evaluates the impact of non-invasive foetal Rhesus D (RHD) status determination on the costs of managing RHD-negative pregnant women and on the appropriate use of anti-D prophylaxis in a large sample of RHD-negative pregnant women using individual prospectively collected clinical and economic data. METHODS: A prospective two-armed trial of RHD negative pregnant women was performed in 11 French Obstetric Departments. Non-invasive foetal RHD genotyping was performed before 26 weeks' gestation in the experimental arm whereas the control arm participants received usual care. The costs associated with patient management in relation to their RHD negative status (biological tests, anti-D prophylaxis and visits) were calculated from inclusion to the end of the postpartum period. The costs of hospital admissions during pregnancy and delivery were also determined. RESULTS: A total of 949 patients were included by 11 centres between 2009 and 2012, and 850 completed follow-up, including medical and biological monitoring. Patients were separated into two groups: the genotyping group (n=515) and the control group (n=335). The cost of the genotyping was estimated at 140 euros per test. The total mean cost per patient was estimated at 3,259 (SD ± 1,120) and 3,004 (SD ± 1,004) in the genotyping and control groups respectively. The cost of delivery represented three quarters of the total cost in both groups. The performance of managing appropriately RHD negative anti-D prophylaxis was 88% in the genotyping group, versus 65% in the control group. Using the costs related to RHD status (biological tests, anti-D immunoglobulin injections and visits) the incremental cost-effectiveness ratio (ICER) was calculated to be 578 for each percentage gain in women receiving appropriate management. CONCLUSION: Early knowledge of the RHD status of the foetus using non-invasive foetal RHD genotyping significantly improved the management of RHD negative pregnancies with a small increase in cost. TRIAL REGISTRATION: Clinical trials registry- NCT00832962 -13 January 2009 - retrospectively registered.
Asunto(s)
Feto/inmunología , Técnicas de Genotipaje , Atención Prenatal , Isoinmunización Rh , Sistema del Grupo Sanguíneo Rh-Hr/genética , Globulina Inmune rho(D)/uso terapéutico , Análisis Costo-Beneficio , Femenino , Francia , Genotipo , Técnicas de Genotipaje/economía , Técnicas de Genotipaje/métodos , Humanos , Factores Inmunológicos/uso terapéutico , Embarazo , Resultado del Embarazo/epidemiología , Atención Prenatal/economía , Atención Prenatal/métodos , Diagnóstico Prenatal/economía , Diagnóstico Prenatal/métodos , Isoinmunización Rh/sangre , Isoinmunización Rh/prevención & control , Globulina Inmune rho(D)/inmunologíaRESUMEN
BACKGROUND: The optimal strategy to monitor RhD-immunized pregnancies is not evident. Whether a quantitative analysis of anti-D antibodies adds valuable information to anti-D titre is unclear. The aim of this study was to evaluate the relevance of anti-D quantification in routine monitoring of RhD-immunized pregnancies. MATERIALS AND METHODS: In a retrospective study, 64 consecutive pregnancies in 61 immunized women with anti-D titre ≥128 at any time during pregnancy were included. According to routine, at titre ≥128, anti-D quantification was performed by flow cytometry and the peak systolic velocity in the middle cerebral artery was measured by ultrasound. Decisions for treatment with intrauterine blood transfusion were based on increased peak systolic velocity in the middle cerebral artery. RESULTS: Increasing anti-D concentrations correlated well to increasing anti-D titres, but at each titre value, there was a large interindividual variation, in the determined anti-D concentration. Intrauterine transfusions were initiated in 35 pregnancies according to algorithms based on ultrasound measurements, at anti-D concentrations of 2·4-619 IU/ml and titre 128-16 000. Sixty pregnancies resulted in a live-born child, three in miscarriage and one in termination of pregnancy. During the perinatal care in the neonatal intensive care unit, thirty-one of the neonates were treated with blood exchange transfusions and/or red cell transfusions and 47 were treated with phototherapy. CONCLUSION: Anti-D quantification does not add further information compared to anti-D titre, in defining a critical level to start monitoring RhD-immunized pregnancies with Doppler ultrasound.
Asunto(s)
Monitorización Inmunológica/métodos , Resultado del Embarazo/epidemiología , Isoinmunización Rh/sangre , Globulina Inmune rho(D)/sangre , Ultrasonografía Doppler/métodos , Adulto , Femenino , Humanos , Monitorización Inmunológica/normas , Embarazo , Isoinmunización Rh/diagnóstico por imagen , Isoinmunización Rh/epidemiología , Ultrasonografía Doppler/normasAsunto(s)
Tipificación y Pruebas Cruzadas Sanguíneas/instrumentación , Sistema del Grupo Sanguíneo Rh-Hr/sangre , Automatización , Tipificación y Pruebas Cruzadas Sanguíneas/métodos , Femenino , Humanos , Indicadores y Reactivos , Fenotipo , Embarazo , Isoinmunización Rh/sangre , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: Immunosuppressed, RhD-negative oncology patients tend to have lower rates of sensitization to the D antigen when they receive transfusion with RhD-positive blood components. Clinical factors associated with alloimmunization to the D antigen in RhD-negative oncology patients when they receive transfusion with RhD-positive red blood cells (RBCs) have not been well defined. STUDY DESIGN AND METHODS: This was a 4-year, retrospective analysis identifying RhD-negative oncology patients who received RhD-positive RBCs and were not previously alloimmunized to the D antigen. Age, sex, race, ABO group, primary oncology diagnosis, and numbers of RhD-incompatible RBC transfusions were recorded. The association between antibody formation and clinical factors was studied. The incidence of alloanti-D was calculated from a subsequent antibody-detection test performed at least 28 days after receipt of the first transfusion of RhD-positive RBCs. RESULTS: In total, 545 RhD-negative oncology patients received 4295 RhD-positive RBC transfusions. Of these, 76 (14%) became alloimmunized to the D antigen. Diagnosis type was the only factor significantly associated with responder status. The logistic regression model indicated that patients who had myelodysplastic syndrome or solid malignancies were more likely to be responders than those who had acute leukemia. CONCLUSION: We measured a 14% sensitization rate to the D antigen in our RhD-negative oncology population. The rate of alloimmunization was higher in patients who had solid cancers (22.6%) or myelodysplastic syndrome (23%) compared with those who had other hematologic malignancies (7%). Knowledge of diagnoses that predispose to RhD alloimmunization enables better utilization of RhD-negative RBCs during times of shortage.
Asunto(s)
Transfusión de Eritrocitos , Neoplasias/terapia , Isoinmunización Rh/epidemiología , Sistema del Grupo Sanguíneo Rh-Hr/sangre , Factores de Edad , Anciano , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Neoplasias/sangre , Isoinmunización Rh/sangre , Globulina Inmune rho(D)/sangre , Factores SexualesRESUMEN
OBJECTIVE: This study was aimed to evaluate whether maternal dried blood spots could be a potential source for the noninvasive fetal RHD genotyping, serving as a combined one-step test for both the First Trimester Screen and the fetal RHD genotyping. METHOD: Both the maternal dried blood spots and the peripheral blood samples from 19 RhD-negative pregnant women were obtained during the First Trimester Screen. DNA was extracted and sequential real-time PCRs were performed to determine the fetal RHD genotypes. Fetal RhD serological types were obtained after delivery. This study was approved by the Institutional Review Board, and informed consents were obtained. RESULTS: A total of 19/19 fetal RHD genotyping with maternal DBS were consistent with the follow-up serological RhD test results after birth. Eleven were RhD positive, and eight were RhD negative (RHD deletion or RHD-CE-D = 6, RHD pseudogene = 1, RHDVI = 1). Sensitivity = 100%, specificity = 100%, positive predictive value = 100%, negative predictive value = 100%. A total of 18/19 fetal gender were determined correctly with maternal DBS. One female fetus was falsely determined as male. Sensitivity = 100%, specificity = 91.6%, positive predictive value = 87.5%, negative predictive value = 100%. CONCLUSION: Maternal dried blood spots, with the benefits of flexible sample transportation and processing, could be utilized for the noninvasive prenatal fetal RHD genotyping and potentially be incorporated into the routine First Trimester Screen. Larger scale study is in progress to implement fetal RHD genotyping in routine prenatal care. © 2017 John Wiley & Sons, Ltd.
Asunto(s)
Pruebas con Sangre Seca , Enfermedades Fetales/diagnóstico , Primer Trimestre del Embarazo/sangre , Diagnóstico Prenatal/métodos , Sistema del Grupo Sanguíneo Rh-Hr/sangre , Femenino , Enfermedades Fetales/sangre , Genotipo , Técnicas de Genotipaje/métodos , Humanos , Masculino , Madres , Embarazo , Reacción en Cadena en Tiempo Real de la Polimerasa , Isoinmunización Rh/sangre , Sistema del Grupo Sanguíneo Rh-Hr/análisis , Sensibilidad y EspecificidadRESUMEN
BACKGROUND: This study aims at alloantibody screening, determination of the types of these antibodies in multiple-transfused patients with chronic hematologic diseases. PATIENTS AND METHODS: This descriptive study was performed on 240 patients with chronic hematological diseases referred to public hospitals in Iran. Single blood sample was taken and tested for the presence of antibodies. In case of a positive antibody screening, antibody identification was performed using granulocyte agglutination test (GAT), granulocyte indirect immunofluorescence test (GIIFT), platelet indirect immunofluorescence test (PIIFT), monoclonal antibody-specific immobilization of platelet antigen (MAIPA) and panel cells. RESULTS: Out of 240 patients, 105 patients (43.75 %) had been alloimmunized. The incidence of alloantibodies against red blood cells (RBCs) in positive alloantibodies patients were 84.76% (89/105). The most common alloantibody was against antigens of the kell (anti-K) and Rh (anti-E) and (anti D) systems (46.66%, 18.09% and 11.43% respectively). The overall incidence of anti- human leukocyte antigen (HLA) antibodies were 65.7% (69/105). Polymorphonuclear (PMN)-specific antibodies were found in 6.66% (7/105). Also from 105 patients, 14 patients had alloantibodies against platelet. DISCUSSION: In general, it is recommend that to decrease the rate of alloantibody synthesis, the packed cells should be cross matched for minor blood groups especially for Rh (E) and kell. In addition, the use of leukodepleted blood products can decrease the frequency of alloimmunization against platelet (PLT), PMN and HLA antigens.
Asunto(s)
Plaquetas/inmunología , Eritrocitos/inmunología , Granulocitos/inmunología , Sistema del Grupo Sanguíneo de Kell/inmunología , Isoinmunización Rh/inmunología , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Reacción a la Transfusión , Adolescente , Adulto , Anciano , Plaquetas/metabolismo , Niño , Eritrocitos/metabolismo , Femenino , Granulocitos/metabolismo , Humanos , Isoanticuerpos/sangre , Isoanticuerpos/inmunología , Sistema del Grupo Sanguíneo de Kell/sangre , Masculino , Persona de Mediana Edad , Isoinmunización Rh/sangre , Isoinmunización Rh/epidemiología , Sistema del Grupo Sanguíneo Rh-Hr/sangreRESUMEN
OBJECTIVE: To evaluate the effect of red blood cell (RBC) antibody screening in the 27th week of pregnancy in Rhc-negative women, on detection of alloimmunisation, undetected at first trimester screening ('late' alloimmunisation), and subsequent haemolytic disease of the fetus and newborn (HDFN), to assess risk factors for late alloimmunisation. DESIGN: Prospective cohort and nested case-control study. SETTING: The Netherlands. POPULATION: Two-year nationwide cohort. METHODS: Prospective inclusion of Rhc-negative women with negative first trimester screening and of screen-negative controls. Assessment of incidence and numbers needed to screen (NNS) of late alloimmunisation and HDFN; logistic regression analysis to establish risk factors for late alloimmunisation. MAIN OUTCOME MEASURES: Late alloimmunisation, HDFN. RESULTS: Late alloimmunisation occurred in 99 of 62 096 (0.159%) Rhc-negative women; 90% had c/E antibodies and 10% non-Rhesus antibodies. Severe HDFN (fetal/neonatal transfusion) occurred in two of 62 096 (0.003%) of Rhc-negative women and 2% of late alloimmunisations; moderate HDFN (phototherapy) occurred in 20 children [22.5%; 95% confidence interval (CI), 13.8-31.1%]. Perinatal survival was 100%. The NNS to detect one HDFN case was 2823 (31 048 for severe, 3105 for moderate HDFN). Significant risk factors were former blood transfusion [odds ratio (OR), 10.4; 95% CI, 1.14-94.9], parity (P-1: OR, 11.8; 95% CI, 3.00-46.5; P > 1: OR, 7.77; 95% CI, 1.70-35.4) and amniocentesis/chorionic villus sampling during current pregnancy (OR, 9.20; 95% CI, 1.16-72.9). CONCLUSIONS: Additional screening of Rhc-negative women improved the detection of late alloimmunisation and HDFN, facilitating timely treatment, with a NNS of 2823. Independent risk factors for late alloimmunisation were blood transfusion, parity and chorionic villus sampling/amniocentesis in the current pregnancy. The occurrence of most factors before the current pregnancy suggests a secondary immune response explaining most late alloimmunisations. TWEETABLE ABSTRACT: Third trimester screening for alloimmunisation in Rhc-neg women improves detection and treatment of severe HDFN.
Asunto(s)
Eritroblastosis Fetal/sangre , Eritroblastosis Fetal/epidemiología , Tamizaje Masivo/estadística & datos numéricos , Isoinmunización Rh/sangre , Isoinmunización Rh/epidemiología , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Amniocentesis/estadística & datos numéricos , Transfusión Sanguínea/estadística & datos numéricos , Muestra de la Vellosidad Coriónica/estadística & datos numéricos , Eritroblastosis Fetal/diagnóstico , Eritroblastosis Fetal/terapia , Femenino , Humanos , Incidencia , Recién Nacido , Isoanticuerpos/sangre , Países Bajos/epidemiología , Paridad , Embarazo , Tercer Trimestre del Embarazo , Evaluación de Programas y Proyectos de Salud , Isoinmunización Rh/diagnóstico , Isoinmunización Rh/terapia , Factores de Riesgo , Índice de Severidad de la Enfermedad , Tasa de SupervivenciaRESUMEN
Rh alloimmunization remains a potentially devastating complication of pregnancy, with fetal anemia causing hydrops and intrauterine death. Intrauterine transfusion is the standard treatment, but is particularly dangerous before 20 weeks gestation. When the need for intrauterine transfusion is anticipated early in pregnancy, immune-modulating therapies such as plasmapheresis and IVIG have been used to delay transfusion to a later gestational age. We report a 35-year-old G5P1 Rh(D)-negative woman with severe Rh alloimmunization managed successfully with sequential plasmapheresis, intravenous immune globulin and intrauterine transfusion. The optimal plasmapheresis treatment protocol and incremental benefit of IVIG remains unknown.
Asunto(s)
Transfusión de Sangre Intrauterina , Eritroblastosis Fetal/terapia , Inmunoglobulinas Intravenosas/administración & dosificación , Plasmaféresis , Isoinmunización Rh/terapia , Adulto , Eritroblastosis Fetal/sangre , Femenino , Humanos , Embarazo , Isoinmunización Rh/sangreRESUMEN
Clinicians sometimes are confronted with the challenge of transfusing haemorrhaging Rhesus (Rh) D negative patients with Rh D positive blood to save their lives. There are concerns about alloimmunization and future haemolytic disease of the newborn in women of the reproductive age. Another fear is transfusion reaction if they receive another Rh D positive blood in future. We present a 32-year-old Rh D negative woman, who had postpartum haemorrhage in her first pregnancy and was transfused with Rh D positive blood because of unavailability of Rh D negative blood. She did not receive anti D immunoglobin but subsequently had a normal term pregnancy of an Rh positive fetus without any detectable anti D antibodies throughout the pregnancy. In life threatening situations from obstetric haemorrhage, transfusion of Rh D negative women with Rh D positive blood should be considered as the last resort.
Asunto(s)
Transfusión Sanguínea/métodos , Complicaciones Hematológicas del Embarazo/inmunología , Isoinmunización Rh/tratamiento farmacológico , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Globulina Inmune rho(D)/sangre , Adulto , Femenino , Humanos , Factores Inmunológicos/administración & dosificación , Recién Nacido , Embarazo , Isoinmunización Rh/sangre , Globulina Inmune rho(D)/administración & dosificaciónRESUMEN
BACKGROUND: Fetal-maternal hemorrhage is usually spontaneous and goes undetected but can be associated with adverse perinatal outcomes. CASE: We describe the detection of a fetal-maternal hemorrhage by abrupt disappearance of prophylactic anti-D on antibody screen in an Rh-negative mother with dichorionic twins admitted for atrial flutter of one twin. Both rosette and Kleihauer-Betke tests were positive. The diagnosis was confirmed by anemia in one twin at birth. CONCLUSION: Fetal-maternal hemorrhage requires a high index of suspicion for diagnosis. An unexpected sudden decline in Rh immune globulin-related anti-D may be an indication of fetal-maternal hemorrhage.
Asunto(s)
Transfusión Fetomaterna/diagnóstico , Factores Inmunológicos/sangre , Isoinmunización Rh/prevención & control , Globulina Inmune rho(D)/sangre , Adulto , Femenino , Transfusión Fetomaterna/sangre , Transfusión Fetomaterna/inmunología , Humanos , Factores Inmunológicos/uso terapéutico , Embarazo , Embarazo Gemelar , Isoinmunización Rh/sangre , Globulina Inmune rho(D)/uso terapéuticoAsunto(s)
Tipificación y Pruebas Cruzadas Sanguíneas/métodos , Moléculas de Adhesión Celular/inmunología , Isoinmunización Rh/sangre , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Globulina Inmune rho(D)/sangre , Adolescente , Adulto , Anciano de 80 o más Años , Especificidad de Anticuerpos , Moléculas de Adhesión Celular/genética , Membrana Eritrocítica/inmunología , Reacciones Falso Positivas , Femenino , Neoplasias Hematológicas/terapia , Humanos , Inmunización Pasiva , Recién Nacido , Masculino , Embarazo , Isoinmunización Rh/diagnóstico , Isoinmunización Rh/inmunología , Globulina Inmune rho(D)/inmunología , Globulina Inmune rho(D)/uso terapéutico , Adulto JovenRESUMEN
OBJECTIVE: Investigation of the accuracy and national implementation of foetal Rhesus-D typing (fRhD), introduced in 2011 for RhD-negative pregnant women. DESIGN: Descriptive, national study. METHOD: Results of fRhD in pregnant women in the first year after implementation were compared to results from cord blood RhD typing of the child. RESULTS: 0.05% of the fRhD results was false negative (9/18.383; 95% CI: 0.02-0.09), and 0.85% was false positive (157/18.383; 95% CI: 0.73-1.00). fRhD was incorrectly omitted in fewer than 1% of pregnant women. In 96.1% of the pregnant women, antenatal administration of anti-D prophylaxis was recorded. Recording of postnatal anti-D administration turned out to be lower (92%), but locally recorded data showed that postnatal anti-D was omitted in fewer than 2% of cases. CONCLUSION: The percentage of false negative fRhD was statistically significantly lower (p < 0.05) than the critical limit of 0.25% determined beforehand by the Programme Committee of the Dutch Antenatal Screening Programme for Infectious Diseases and Erythrocyte Immunisation. The percentage of false positive fRhD was considered acceptable, and implementation of fRhD was more or less complete. Routine RhD-typing on cord blood was therefore omitted from January 2013. Antenatal and postnatal anti-D administration is now specifically indicated for RhD-negative pregnant women when fRhD is positive, thus saving about 10,000 unnecessary antenatal anti-D administrations per year. RhD-typing on cord blood is now performed only if the RhD blood type of the child of a RhD-negative mother is unknown at delivery, if a positive fRhD was found for multiple births, and in exceptional situations, e.g. if fRhD typing is not possible due to a rare genetic variation.